Pricing Log in Create free account
Saturday 17 October 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

156.19 1.18 −0.75%
Market cap
$195.1B
P/E
0.0×
Fwd P/E
−46.2×
Dividend yield
2.08%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Gilead Sciences, Inc. (GILD) P/B ratio

Alert me on P/B ratio

As of 16 October 2026, Gilead Sciences, Inc. (GILD) trades at a P/B ratio of 16.5×. Over the past ten years it has ranged from 3.4× (December 2018) to 16.7× (October 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 5.0× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 6.8× 12.80%
FY2024 6.0× 31.06%
FY2023 4.6× (9.62%)
FY2022 5.1× 16.70%
FY2021 4.3× 7.73%
FY2020 4.0× 10.31%
FY2019 3.6× (3.36%)
FY2018 3.8× (20.19%)
FY2017 4.7× (7.88%)
FY2016 5.1× (33.84%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 13.4× 81.01%
Mar 2026 7.4× 9.43%
Dec 2025 6.8× 4.98%
Sep 2025 6.4× (8.73%)
42 more quarters

Against its own ten years

Low 3.4× High 16.7×
Ten-year median 4.7×
Current reading's percentile 100

P/B ratio against peers

Company P/B ratio
PFE Pfizer Inc. compare 2.0×
GSK GSK PLC Sponsored ADR compare 4.3×
NVO Novo Nordisk A/S compare 5.0×
AZN AstraZeneca PLC compare 5.1×
BMY Bristol Myers Squibb Company compare 5.5×
NVS Novartis AG compare 6.8×
MRK Merck & Co., Inc. compare 8.6×
GILD Gilead Sciences, Inc. 16.5×
AMGN Amgen Inc. compare 20.0×
Drug Manufacturers General industry median 5.0×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on GILD